Literature DB >> 25851217

Respiratory syncytial virus infection in older adults: an under-recognized problem.

Angela R Branche1, Ann R Falsey.   

Abstract

Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA virus and member of the Paramyxoviridae family of the genus Pneumovirus that was first reported as a major pathogen in pediatric populations. However, since its discovery, RSV has not infrequently been detected in adults. Reinfection occurs throughout life, with more severe disease occurring in older adults, immunocompromised patients, and those with underlying cardiopulmonary disease. Initially described as the cause of nursing home outbreaks of respiratory disease, there is a now significant body of literature describing the clinical importance of RSV in older adults in a multitude of settings including long-term care, adult daycares, and in community-dwelling adults. Moreover, recent reports from China and other countries emphasize that RSV is a global pathogen that will become increasingly important in developed nations with aging populations. Annual attack rates in the USA range from 2 to 10% in community-dwelling older adults and 5-10% in older adults living in congregate settings. Population-based calculations of the proportion of acute respiratory illnesses attributable to RSV estimate that 11,000 elderly persons die annually in the USA of illnesses related to RSV infection. Clinical manifestations of RSV infections are similar to that of other viral respiratory pathogens and include cough, nasal congestion, rhinorrhea, sore throat, and dyspnea. Lower respiratory tract disease is common and may result in respiratory failure (8-13%) or death (2-5%). Recent advances in molecular diagnostics have made it possible to rapidly identify RSV infection using nucleic acid amplification tests, although clinicians will need to suspect the diagnosis when viral activity is high. At the present time, treatment is supportive. Effective antiviral agents for the treatment and vaccines for prevention of RSV remain a significant unmet medical need in the older adult population.

Entities:  

Mesh:

Year:  2015        PMID: 25851217     DOI: 10.1007/s40266-015-0258-9

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  104 in total

1.  Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness.

Authors:  Ann R Falsey; Maria A Formica; Edward E Walsh
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Epidemiology of acute respiratory illness during an influenza outbreak in a nursing home. A prospective study.

Authors:  P A Gross; M Rodstein; J R LaMontagne; R A Kaslow; A J Saah; S Wallenstein; R Neufeld; C Denning; P Gaerlan; G V Quinnan
Journal:  Arch Intern Med       Date:  1988-03

Review 3.  Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature.

Authors:  M I Hertz; J A Englund; D Snover; P B Bitterman; P B McGlave
Journal:  Medicine (Baltimore)       Date:  1989-09       Impact factor: 1.889

4.  Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants.

Authors:  S Krinzman; N Basgoz; R Kradin; J A Shepard; D B Flieder; C D Wright; J C Wain; L C Ginns
Journal:  J Heart Lung Transplant       Date:  1998-02       Impact factor: 10.247

5.  An outbreak of an influenza-like illness in a nursing home.

Authors:  D Osterweil; D Norman
Journal:  J Am Geriatr Soc       Date:  1990-06       Impact factor: 5.562

6.  Respiratory syncytial virus and influenza A infections in the hospitalized elderly.

Authors:  A R Falsey; C K Cunningham; W H Barker; R W Kouides; J B Yuen; M Menegus; L B Weiner; C A Bonville; R F Betts
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

7.  The potential influence of common viral infections diagnosed during hospitalization among critically ill patients in the United States.

Authors:  Makesha Miggins; Anjum Hasan; Samuel Hohmann; Frederick Southwick; George Casella; Denise Schain; Huazhi Liu; Azra Bihorac; Lyle Moldawer; Philip Efron; Darwin Ang
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

8.  The effect of steroid use in hospitalized adults with respiratory syncytial virus-related illness.

Authors:  F Eun-Hyung Lee; Edward E Walsh; Ann R Falsey
Journal:  Chest       Date:  2011-05-12       Impact factor: 9.410

9.  Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness.

Authors:  Ann R Falsey; Janet E McElhaney; Jiri Beran; Gerrit A van Essen; Xavier Duval; Meral Esen; Florence Galtier; Pierre Gervais; Shinn-Jang Hwang; Peter Kremsner; Odile Launay; Geert Leroux-Roels; Shelly A McNeil; Andrzej Nowakowski; Jan Hendrik Richardus; Guillermo Ruiz-Palacios; Suzanne St Rose; Jeanne-Marie Devaster; Lidia Oostvogels; Serge Durviaux; Sylvia Taylor
Journal:  J Infect Dis       Date:  2014-01-29       Impact factor: 5.226

10.  Respiratory syncytial virus: an important cause of acute respiratory illness among young adults undergoing military training.

Authors:  Matthew K O'Shea; Christopher Pipkin; Patricia A Cane; Gregory C Gray
Journal:  Influenza Other Respir Viruses       Date:  2007 Sep-Nov       Impact factor: 4.380

View more
  47 in total

1.  Alcohol potentiates RSV-mediated injury to ciliated airway epithelium.

Authors:  Todd A Wyatt; Kristina L Bailey; Samantha M Simet; Kristi J Warren; Jenea M Sweeter; Jane M DeVasure; Jaqueline A Pavlik; Joseph H Sisson
Journal:  Alcohol       Date:  2018-07-26       Impact factor: 2.405

2.  Respiratory syncytial virus hospitalization in middle-aged and older adults.

Authors:  Ryan E Malosh; Emily T Martin; Amy P Callear; Joshua G Petrie; Adam S Lauring; Lois Lamerato; Alicia M Fry; Jill Ferdinands; Brendan Flannery; Arnold S Monto
Journal:  J Clin Virol       Date:  2017-09-07       Impact factor: 3.168

3.  A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Barney S Graham; Sang Moo Kang
Journal:  Virology       Date:  2019-05-28       Impact factor: 3.616

Review 4.  Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Authors:  Cameron Griffiths; Steven J Drews; David J Marchant
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 5.  Innate immune responses in the ageing lung.

Authors:  D M Boe; L A Boule; E J Kovacs
Journal:  Clin Exp Immunol       Date:  2016-11-02       Impact factor: 4.330

6.  On the Relative Role of Different Age Groups During Epidemics Associated With Respiratory Syncytial Virus.

Authors:  Edward Goldstein; Hieu H Nguyen; Patrick Liu; Cecile Viboud; Claudia A Steiner; Colin J Worby; Marc Lipsitch
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

7.  Determining the Seasonality of Respiratory Syncytial Virus in the United States: The Impact of Increased Molecular Testing.

Authors:  Claire M Midgley; Amber K Haynes; Jason L Baumgardner; Christina Chommanard; Sara W Demas; Mila M Prill; Glen R Abedi; Aaron T Curns; John T Watson; Susan I Gerber
Journal:  J Infect Dis       Date:  2017-08-01       Impact factor: 5.226

8.  Localization of the T-cell response to RSV infection is altered in infant mice.

Authors:  Katherine M Eichinger; Jessica L Kosanovich; Kerry M Empey
Journal:  Pediatr Pulmonol       Date:  2017-11-08

Review 9.  Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Authors:  Charles J Russell; Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2015-12-09       Impact factor: 5.217

Review 10.  A multifaceted approach to RSV vaccination.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Trudy G Morrison; Stefanie N Vogel
Journal:  Hum Vaccin Immunother       Date:  2018-06-19       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.